NovoCure (NASDAQ:NVCR) Issues Earnings Results, Beats Expectations By $0.19 EPS

NovoCure (NASDAQ:NVCR) released its quarterly earnings data on Thursday. The medical equipment provider reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.19, FiscalAI reports. NovoCure had a negative return on equity of 50.29% and a negative net margin of 27.66%.The business had revenue of $174.35 million for the quarter, compared to analyst estimates of $174.40 million. During the same period last year, the firm posted ($0.61) earnings per share. NovoCure’s revenue was up 8.2% compared to the same quarter last year.

Here are the key takeaways from NovoCure’s conference call:

• Novocure received FDA approval for Optune Pax for locally advanced pancreatic cancer, has begun U.S. launch activities, and filed regulatory applications in Europe and Japan.
• The company reported record 2025 net revenue of $655 million (Q4 revenue $174M) and issued 2026 guidance of $675M–$705M, while targeting adjusted EBITDA of –$20M to break even, reflecting a push toward profitability.
• Several near-term clinical catalysts are scheduled for 2026, including top-line readouts from PANOVA‑4 next month and the Phase 3 TRIDENT trial in Q2, plus expected completion of KEYNOTE‑D58 enrollment by year-end.
• Despite revenue growth, Novocure reported a full‑year net loss of $136 million and negative adjusted EBITDA (‑$34M for 2025), sees pressured gross margins (mid‑70s expected in 2026), and has drawn on credit while carrying $448 million in cash after repaying convertible notes.
• Leadership and operational changes include the resignation of the Chief Medical Officer and consolidation of scientific and clinical teams under Chief Innovation Officer Uri Weinberg, and a briefly suspended Medicare billing privilege that was promptly reinstated.

NovoCure Price Performance

NVCR stock traded down $0.16 during mid-day trading on Friday, reaching $13.59. 1,223,951 shares of the company’s stock were exchanged, compared to its average volume of 2,220,407. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.55 and a quick ratio of 1.50. The stock’s 50 day moving average is $12.71 and its 200 day moving average is $12.63. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -8.45 and a beta of 0.73. NovoCure has a 12-month low of $9.82 and a 12-month high of $21.55.

NovoCure News Summary

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 EPS materially beat expectations — loss per share of ($0.22) vs. consensus ($0.41), and a clear improvement vs. ($0.61) a year ago; this earnings surprise supports a constructive near‑term reaction. NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company set FY‑2026 revenue guidance of $675M–$705M, slightly above Street consensus (~$670M), giving revenue visibility that may support multiple expansion if execution matches the outlook. Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
• Positive Sentiment: HC Wainwright raised its price target to $49 with a “buy” rating (a large upside from current levels), which can attract attention from growth‑oriented investors. NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
• Positive Sentiment: Revenue grew ~8% y/y and the company reported record quarterly revenue, reinforcing underlying demand for its therapy as management outlines growth initiatives. NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst coverage is mixed — recent commentary aggregates four ratings and differing views on timing of commercialization and upside, so analyst activity could add volatility. NovoCure Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
• Neutral Sentiment: Earnings call transcript and slides provide detail on strategy and product adoption; these disclosures reduce information asymmetry but require follow‑through to matter for the stock. NovoCure (NVCR) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Despite the beat, NovoCure remains unprofitable (negative net margin ~27.7% and negative ROE ~50.3%) and analysts still model negative EPS for the year; sustained profitability and margin improvement remain key risks. NovoCure: Q4 Earnings Snapshot / MarketBeat
• Negative Sentiment: Management flagged operational challenges on the call; execution risk (reimbursement, adoption, supply/ops) could pressure the stock if guidance proves optimistic. NovoCure Ltd (NVCR) Q4 2025 Earnings Call Highlights

Analyst Ratings Changes

A number of analysts recently commented on NVCR shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Evercore set a $20.00 target price on NovoCure in a research report on Monday, January 5th. Wedbush reaffirmed a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research note on Thursday, January 15th. Finally, HC Wainwright boosted their price objective on shares of NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a report on Thursday. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $26.93.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley raised its position in NovoCure by 453.4% in the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock valued at $65,554,000 after purchasing an additional 4,153,741 shares during the last quarter. Soleus Capital Management L.P. raised its stake in shares of NovoCure by 25.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after acquiring an additional 1,382,888 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in NovoCure by 1,093.2% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock valued at $15,823,000 after purchasing an additional 1,121,192 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in NovoCure in the fourth quarter worth about $11,991,000. Finally, Millennium Management LLC increased its position in NovoCure by 106.5% in the 3rd quarter. Millennium Management LLC now owns 1,335,490 shares of the medical equipment provider’s stock valued at $17,255,000 after acquiring an additional 688,710 shares during the period. Hedge funds and other institutional investors own 84.61% of the company’s stock.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.